Browsing Tag
LYMPHIR
5 posts
Citius Oncology (CTOR) balances LYMPHIR launch momentum with cash runway pressure after Q2 loss
Citius Oncology has LYMPHIR revenue, but cash runway only reaches November 2026. Investors now face launch proof versus dilution risk.
Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization
Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
Citius Oncology (Nasdaq: CTOR) bets on Verix AI to supercharge LYMPHIR’s commercial rollout in CTCL
Find out how Citius Oncology is leveraging Verix AI to power the commercial launch of LYMPHIR and accelerate uptake in CTCL.
Citius Oncology bets on AI-powered sales strategy to fast-track LYMPHIR cancer drug launch
Citius Oncology launches an AI-powered platform to boost LYMPHIR’s commercial debut in CTCL, reshaping oncology sales strategies with precision targeting.